Table 5.
Differences in Adverse Reactions of Live-Attenuated Oxford/AstraZeneca COVID-19 Vaccination Between Hyperlipidemia (n=359) and Non-Hyperlipidemia (n=2657) Groups
| Sign Effect | Category | 1st Dose | 2nd Dose | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipidemia (n=359) | Non-Hyperlipidemia (n=2657) | RR (95% CI) | p-value | Hyperlipidemia (n=359) | None Hyperlipidemia (n=2657) | RR (95% CI) | p-value | ||
| N (%) | N (%) | n(%) | n(%) | ||||||
| Within 30 minutes | Fever, mild headache or high grade fever, severe headache | 4(1.1) | 34(1.3) | 0.9 (0.307to2.46) | 0.792 | 0(0) | 2(0.1) | - | - |
| Chest discomfort or breathing difficulties | - | - | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 5(0.2) | - | - | - | - | - | - | |
| Skin rash /urticaria | 1(0.3) | 5(0.2) | 1.5 (0.173 to 12.7) | 0.72 | 1(0.3) | 0(0) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 2(0.6) | 16(0.6) | 0.9 (0.21 to 4.04) | 0.917 | - | - | - | - | |
| Within 6 hours | Fever, mild headache or high grade fever, severe headache | 36(10) | 225(8.5) | 1.2 (0.83 to 1.75) | 0.324 | 9(2.5) | 41(1.5) | 1.6 (0.79to3.41) | 0.184 |
| Chest discomfort or breathing difficulties | - | - | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 1(0.3) | 20(0.8) | 0.4 (0.5 to 2.75) | 0.33 | 1(0.3) | 2(0.1) | 3.7 (0.335to40.99) | 0.285 | |
| Skin rash /urticaria | 2(0.6) | 23(0.9) | 0.6 (0.15 to 2.73) | 0.548 | 1(0.3) | 3(0.1) | 2.5 (0.256to23.8) | 0.434 | |
| Pain, swelling, redness and warmth at the injection site | 8(2.2) | 65(2.4) | 0.9 (0.43 to 1.91) | 0.801 | 4(1.1) | 14(0.5) | 2.1 (0.69to6.5) | 0.185 | |
| Within 24 hours | Fever, mild headache or high grade fever, severe headache | 131(36.5) | 807(30.4) | 1.3 1.046 to 1.65) | 0.019* | 87(24.2) | 458(17.2) | 1.5 (1.18to1.99) | 0.001* |
| Chest discomfort or breathing difficulties | 1(0.3) | 2(0.1) | 3.7 (0.335 to 40.9) | 0.285 | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 5(1.4) | 60(2.3) | 0.6 (0.244 to 1.53) | 0.294 | 3(0.8) | 10(0.4) | 2.2 (0.611to8.14) | 0.255 | |
| Skin rash /urticaria | 7(1.9) | 78(2.9) | 0.7 (0.301 to 1.43) | 0.301 | 3(0.8) | 15(0.6) | 1.5 (0.428to5.15) | 0.534 | |
| Pain, swelling, redness and warmth at the injection site | 54(15) | 351(13.2) | 1.2 (0.853 to 1.59) | 0.34 | 27(7.5) | 154(5.8) | 1.3 (0.86to2.02) | 0.198 | |
| After 24 hours | Fever, mild headache or high grade fever, severe headache | 49(13.6) | 384(14.5) | 0.9 (0.679 to 1.29) | 0.684 | 46(12.8) | 254(9.6) | 1.4 (0.994to1.94) | 0.054 |
| Chest discomfort or breathing difficulties | 1(0.3) | 3(0.1) | 2.5 (0.256 to 23.8) | 0.434 | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 4(1.1) | 30(1.1) | 1 (0.346 to 2.82) | 0.98 | 4(1.1) | 6(0.2) | 5 (1.39to17.73) | 0.013* | |
| Skin rash /urticaria | 12(3.3) | 44(1.7) | 2.1 (1.074 to 3.93) | 0.03* | 3(0.8) | 15(0.6) | 1.5 (0.428to5.152) | 0.534 | |
| Pain, swelling, redness and warmth at the injection site | 24(6.7) | 191(7.2) | 0.9 (0.6 to 1.44) | 0.728 | 20(5.6) | 123(4.6) | 1.2 (0.78to1.98) | 0.431 | |
| Within 3 days | Fever, mild headache or high grade fever, severe headache | 47(13.1) | 373(14) | 0.9 (0.67 to 1.27) | 0.627 | 45(12.5) | 253(9.5) | 1.4 (0.97to1.91) | 0.074 |
| Chest discomfort or breathing difficulties | 1(0.3) | 2(0.1) | 3.7 (0.34 to 40.99) | 0.285 | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 4(1.1) | 26(1) | 1.1 (0.39 to 3.29) | 0.808 | 4(1.1) | 6(0.2) | 5 (1.39to17.73) | 0.013* | |
| Skin rash /urticaria | 11(3.1) | 38(1.4) | 2.2 (1.103to4.3) | 0.025* | 2(0.6) | 12(0.5) | 1.2 (0.28to5.54) | 0.783 | |
| Pain, swelling, redness and warmth at the injection site | 24(6.7) | 188(7.1) | 0.9 (0.61 to 1.46) | 0.786 | 19(5.3) | 122(4.6) | 1.1 (0.71to1.91) | 0.555 | |
| Within 7 days | Fever, mild headache or high grade fever, severe headache | 49(13.6) | 383(14.4) | 0.9 (0.68 to 1.29) | 0.698 | 46(12.8) | 254(9.6) | 1.4 (0.99to1.94) | 0.054 |
| Chest discomfort or breathing difficulties | 1(0.3) | 3(0.1) | 2.5 (0.26 to 23.8) | 0.434 | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 4(1.1) | 28(1.1) | 1.1 (0.37 to 3.03) | 0.917 | 4(1.1) | 6(0.2) | 5 (1.39to17.73) | 0.013* | |
| Skin rash /urticaria | 12(3.3) | 42(1.6) | 2.2 (1.12 to 4.13) | 0.021* | 3(0.8) | 15(0.6) | 1.5 (0.428to5.15) | 0.534 | |
| Pain, swelling, redness and warmth at the injection site | 24(6.7) | 191(7.2) | 0.9 (0.6 to 1.44) | 0.728 | 20(5.6) | 123(4.6) | 1.2 (0.78to1.98) | 0.431 | |
Note: *is significance with alpha=0.05.